Kelly Davio


Frontline Venetoclax/Obinutuzumab Combo Emerges as Treatment Option for CLL With CKT

June 15th 2019

Othman Al-Sawaf, MD, discusses findings from the CLL14 trial, the rationale for exploring this proposed combination, and shares his thoughts on the emerging treatment paradigms in chronic lymphocytic leukemia.

Second-Generation FLT3 Inhibitors Are Future of Relapsed/Refractory FLT3-Mutant AML Treatment

June 15th 2019

Naval G. Daver, MD, discusses the data that support quizartinib so far, ongoing investigations with this drug in the frontline setting, and the potential for the agent to be approved by the FDA.

Lung Cancer Summit Co-Chair Advocates for Interactive, Evidence-Based Discussions in Evolving Field

May 3rd 2019

Alfredo Addeo, MD, discusses the uniqueness of the 1-day Lung Cancer Summit and recent therapeutic advancements that have occurred in the lung cancer space.

Mok Provides Pembrolizumab Update, Next Steps With Immunotherapy in NSCLC

April 13th 2019

Tony Mok, MD, discusses the KEYNOTE-042 trial and the implications of its findings, and sheds light on the evolving role of immunotherapy in non–small cell lung cancer.

Ramalingam Discusses Osimertinib Efficacy and the Journey to Overcome Acquired Resistance

April 12th 2019

Suresh S. Ramalingam, MD, describes findings with osimertinib, and discusses the emerging body of data exploring primary and acquired resistance mechanisms to the third-generation agent.

Sangro Says Immunotherapy May Be the Future of HCC Treatment

September 16th 2018

Bruno Sangro, MD, discussed the current landscape for systemic therapies, new directions with immunotherapy, and the need for greater research into combination therapies for patients with hepatocellular carcinoma.

ILCA President Highlights Progress, Looks to the Future of HCC Treatment

September 15th 2018

Morris Sherman, MD, PhD, shared his insight on the news and discussions coming out of this year’s meeting, the surge of immunotherapy and targeted therapy research, optimal sequencing approaches, and the challenges that remain in treating patients with hepatocellular carcinoma.

Expert Explores Emerging Role of Personalized Medicine in HCC Treatment

September 14th 2018

Updates to the European Association for the Study of the Liver clinical guidelines introduce more opportunities for individual patient management of hepatocellular carcinoma.